Perspective Therapeutics to present clinical data from three programs at 2026 ASCO

Perspective Therapeutics announced it will present updates on three radiopharmaceutical programs at the 2026 ASCO Annual Meeting, including positive interim data from its [212Pb]VMT01 melanoma study showing 29% response rate and well-tolerated safety profile across all programs. The updates demonstrate continued clinical progress in the company's pipeline of cancer treatment candidates.